Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study.
Gould RL, Rawlinson C, Thompson B, Weeks K, Gossage-Worrall R, Cantrill H, Serfaty MA, Graham CD, McCracken LM, White D, Howard RJ, Bursnall M, Bradburn M, Al-Chalabi A, Orrell R, Chhetri SK, Noad R, Radunovic A, Williams T, Young CA, Dick D, Lawrence V, Goldstein LH, Young T, Ealing J, McLeod H, Williams N, Weatherly H, Cave R, Chiwera T, Pagnini F, Cooper C, Shaw PJ, McDermott CJ; and the COMMEND Collaboration Group. Gould RL, et al. Among authors: chhetri sk. Pilot Feasibility Stud. 2023 Jul 7;9(1):116. doi: 10.1186/s40814-023-01354-7. Pilot Feasibility Stud. 2023. PMID: 37420261 Free PMC article.
Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Malaspina A, Mills R, Tennant A. Young CA, et al. Among authors: chhetri sk. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):400-409. doi: 10.1080/21678421.2024.2322539. Epub 2024 Mar 1. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38426231 Free article.
Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.
Gould RL, McDermott CJ, Thompson BJ, Rawlinson CV, Bursnall M, Bradburn M, Kumar P, Turton EJ, White DA, Serfaty MA, Graham CD, McCracken LM, Goldstein LH, Al-Chalabi A, Orrell RW, Williams T, Noad R, Baker I, Faull C, Lambert T, Chhetri SK, Ealing J, Hanratty A, Radunovic A, Gunawardana N, Meadows G, Gorrie GH, Young T, Lawrence V, Cooper C, Shaw PJ, Howard RJ; COMMEND Collaboration Group. Gould RL, et al. Among authors: chhetri sk. Lancet. 2024 May 9:S0140-6736(24)00533-6. doi: 10.1016/S0140-6736(24)00533-6. Online ahead of print. Lancet. 2024. PMID: 38735299 Free article.
A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M, Lo Giudice M, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Nicolini G, Vanacore N, Dickie B, Albanese A, Puopolo M; TUDCA-ALS Study Group. Lombardo FL, et al. Trials. 2023 Dec 5;24(1):792. doi: 10.1186/s13063-023-07638-w. Trials. 2023. PMID: 38053196 Free PMC article. Clinical Trial.
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Prevalence, treatment and correlates of depression in multiple sclerosis.
Young CA, Langdon D, Rog D, Chhetri SK, Tanasescu R, Kalra S, Webster G, Nicholas R, Ford HL, Woolmore J, Paling D, Tennant A, Mills R; TONiC study group. Young CA, et al. Among authors: chhetri sk. Mult Scler Relat Disord. 2024 Apr 26;87:105648. doi: 10.1016/j.msard.2024.105648. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38713965 Free article.
Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Harrower T, Orrell RW, Annadale J, Hanemann CO, Scalfari A, Tennant A, Mills R; TONIC-ALS STUDY GROUP. Young CA, et al. Among authors: chhetri sk. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Mar 11:1-11. doi: 10.1080/21678421.2024.2322545. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38465877
Diagnosing ALS: the Gold Coast criteria and the role of EMG.
Turner MR; UK MND Clinical Studies Group. Turner MR, et al. Pract Neurol. 2022 Jun;22(3):176-178. doi: 10.1136/practneurol-2021-003256. Epub 2022 Jan 6. Pract Neurol. 2022. PMID: 34992096 Free PMC article. No abstract available.
39 results